{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:07:23Z","timestamp":1793984843161,"version":"4.8.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rivermark Medical, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to evaluate the feasibility and safety of the FloStent\u2122, a novel nitinol prostatic stent, in men with LUTS secondary to BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This multi-center, single-arm, one-year study included men aged \u226545 with BPH. Participants underwent FloStent\u2122 implantation using a flexible cystoscope. The primary endpoints were device implantability, tolerability, and device retrievability. Secondary assessments included International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), post-void residual (PVR), and adverse events (AEs) at follow-ups over 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study enrolled 15 participants with a mean age of 58.1 years. All attempts at implantation were successful. Postoperative catheterization was not required in any patient. Significant improvements were observed in IPSS and Qmax. Thirteen AEs were reported, all resolved, with no serious complications. Device retrieval was safely performed using standard urological equipment up to one-year post-implantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This preliminary study indicates that the FloStent\u2122 is a safe and effective treatment option for BPH, providing significant symptom relief and improved urinary function with a favorable risk profile. Further research, including larger, randomized controlled trials, are needed to validate these findings and establish the long-term efficacy and safety of the FloStent\u2122 device.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-00984-7","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:09:50Z","timestamp":1747836590000},"page":"989-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Feasibility and safety study of the Flostent\u2122 system (RAPID-I)"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-7783","authenticated-orcid":false,"given":"Dean","family":"Elterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Perscky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Urena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Codelia-Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kadlec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-2578","authenticated-orcid":false,"given":"Bilal","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"984_CR1","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"AF Awedew","year":"2022","unstructured":"Awedew AF, Han H, Abbasi B, Abassi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3:e754\u201376. https:\/\/doi.org\/10.1016\/S2666-7568(22)00213-6.","journal-title":"Lancet Healthy Longev"},{"key":"984_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1097\/JU.0000000000002231","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA gUIDELINE PART I-initial work-up and medical management [published correction appears in. J Urol. 2021;206:1339. https:\/\/doi.org\/10.1097\/JU.0000000000002231.","journal-title":"J Urol"},{"key":"984_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211:11\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000003698.","journal-title":"J Urol"},{"key":"984_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14728214.2024.2363213","volume":"29","author":"J Winograd","year":"2024","unstructured":"Winograd J, Venishetty N, Codelia-Anjum A, Bhojani N, Elterman D, Zorn KC, et al. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update. Expert Opin Emerg Drugs. 2024;29:205\u201317. https:\/\/doi.org\/10.1080\/14728214.2024.2363213.","journal-title":"Expert Opin Emerg Drugs"},{"key":"984_CR5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/s0022-5347(17)37628-0","volume":"147","author":"HA Doll","year":"1992","unstructured":"Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992;147:1566\u201373. https:\/\/doi.org\/10.1016\/s0022-5347(17)37628-0.","journal-title":"J Urol"},{"key":"984_CR6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2147\/CIA.S414799","volume":"18","author":"AJ Codelia-Anjum","year":"2023","unstructured":"Codelia-Anjum AJ, Berjaoui MB, Khondker A, Elterman D, Zorn KC, Lerner L, et al. Procedural intervention for benign prostatic hyperplasia in men \u2265 age 70 years - a review of published literature. Clin Inter Aging. 2023;18:1705\u201317. https:\/\/doi.org\/10.2147\/CIA.S414799.","journal-title":"Clin Inter Aging"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00345-023-04508-7","volume":"41","author":"AV Nguyen","year":"2023","unstructured":"Nguyen AV, Verma I, Ferreira R, Nguyen DD, Zorn KC, Bhojani N, et al. A scoping review of office-based prostatic stents: past, present, and future of true minimally invasive treatment of benign prostatic hyperplasia. World J Urol. 2023;41:2925\u201332. https:\/\/doi.org\/10.1007\/s00345-023-04508-7.","journal-title":"World J Urol"},{"key":"984_CR8","doi-asserted-by":"publisher","unstructured":"lterman D, Kaplan SA. Reimagining male lower urinary tract symptoms due to benign prostatic hyperplasia treatment: a new approach to first-line interventional therapy. European Urol focus. 2025. https:\/\/doi.org\/10.1016\/j.euf.2024.12.008.","DOI":"10.1016\/j.euf.2024.12.008"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00984-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:48:02Z","timestamp":1764038882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00984-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00984-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK is the president and CEO of Rivermark Medical, Inc. DE is a consultant for Olympus, Boston Scientific, and Procept BioRobotics. BC is a consultant for Olympus, Boston Scientific, Femselect, ARMs, Prodeon Medical, Sumitomo, Zenflow, and Teleflex. He is an advisor for Promaxo, Bright Uro, COSM, and Soundable. The other authors declare that they have no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Comite de Bioetica de la Investigacion del Instituto Commemorativo Gorgas (CBI-ICGES) and the Panama National Health Ministry (registration number: RESESGIS: #2491). All methods were performed in accordance with the approved protocol, relevant guidelnes and regulations, and the principles of the Declaration of Helsinki. All participants provided informed written consent prior to enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided informed written consent prior to study enrollment. No identifiable images or personal data of participants are published in this manauscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}]}}